Upregulation of the CDC25A phosphatase downstream of the NPM/ALK oncogene participates in anaplastic large cell lymphoma enhanced proliferation

Here, we demonstrate that the expression of the dual specificity phosphatase CDC25A, a key regulator of cell cycle progression, is deregulated in Ba/F3 cells expressing the oncogenic protein NPM/ALK and in human cell lines derived from NPM/ALK-positive anaplastic large cell lymphomas (ALCL). Both transcriptional and post-translational mechanisms account for the constitutive expression of the protein, and the PI3K/Akt pathway is essential for this process. Importantly, pharmacological inhibition of CDC25 dramatically inhibits the proliferation of NPM/ALK-expressing cells, while moderately affecting the proliferation of control Ba/F3 cells. RNA interference-mediated down-regulation of CDC25A confirmed that NPM/ALK-expressing cells are highly dependent on this protein for their proliferation. Moreover, similar PI3K/AKt-mediated constitutive expression of CDC25A takes place down-stream of other hematological oncogenes, including BCR/ABL in Chronic Myeloid Leukemia and FLT3-ITD in Acute Myeloid Leukemia. Altogether, our data point to the functional link between hematopoietic oncogenic tyrosine kinases and the G1 cell cycle regulator CDC25A, and we propose that this protein may be a potential therapeutic target in ALCL and other hematological malignancies.

[1]  B. Ducommun,et al.  IRC‐083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells , 2009, International journal of cancer.

[2]  E. Appella,et al.  GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. , 2008, Cancer cell.

[3]  D. Nimbalkar,et al.  Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. , 2007, Cancer research.

[4]  Bernard Ducommun,et al.  CDC25 phosphatases in cancer cells: key players? Good targets? , 2007, Nature Reviews Cancer.

[5]  K. Engeland,et al.  p53 downregulates expression of the G1/S cell cycle phosphatase Cdc25A , 2007, Oncogene.

[6]  P Wlodarski,et al.  Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf , 2007, Oncogene.

[7]  N. Heerema,et al.  Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. , 2007, Cancer research.

[8]  B. Ducommun,et al.  Cell adhesion regulates CDC25A expression and proliferation in acute myeloid leukemia. , 2006, Cancer Research.

[9]  G. Rassidakis,et al.  Differential expression of cyclin D3 in ALK+ and ALK- anaplastic large cell lymphoma. , 2005, Human pathology.

[10]  D. Levy,et al.  Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target , 2005, Nature Medicine.

[11]  Arnaud M. Vigneron,et al.  The STAT3 Transcription Factor Is a Target for the Myc and Riboblastoma Proteins on the Cdc25A Promoter* , 2005, Journal of Biological Chemistry.

[12]  G. Rassidakis,et al.  Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. , 2005, Blood.

[13]  T. Skorski,et al.  NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner. , 2004, Experimental hematology.

[14]  T. McDonnell,et al.  Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma , 2004, Oncogene.

[15]  L. Busino,et al.  Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis , 2004, Oncogene.

[16]  J. Bartek,et al.  Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines , 2003, Oncogene.

[17]  G. Delsol,et al.  Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. , 2003, Blood.

[18]  G. Inghirami,et al.  NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. , 2003, Blood.

[19]  M. Wasik,et al.  Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. , 2001, Cancer research.

[20]  S. Pileri,et al.  CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. , 2000, Blood.

[21]  N. Mailand,et al.  Involvement of Myc Activity in a G1/S-Promoting Mechanism Parallel to the pRb/E2F Pathway , 2000, Molecular and Cellular Biology.

[22]  R. Prywes,et al.  Serum-Induced Expression of the cdc25AGene by Relief of E2F-Mediated Repression , 1999, Molecular and Cellular Biology.

[23]  D. Beach,et al.  Cdc25 cell-cycle phosphatase as a target of c-myc , 1996, Nature.

[24]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.